Hongfei Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongfei Lou has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Luo Zhang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
20 shared publications - Chengshuo Wang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
14 shared publications - Yanran Huang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
5 shared publications - Yang Wang
Beijing Key Laboratory of Nasal diseases, Beijing Institute of Otolaryngology, Beijing, China
4 shared publications - Kuiji Wang
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China
3 shared publications - Yuan Zhang
Department of Allergy Beijing TongRen Hospital, Capital Medical University Beijing China
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by UK Scientific Publishing Limited in ENT Updates
- Vol. 16 (4) , 24-49
Autoimmune Inner Ear Disease at the Otology–Rheumatology Interface: Mechanisms, Diagnosis and Treatment
Autoimmune inner ear disease (AIED) encompasses immune-mediated sensorineural hearing loss occurring either in isolation or in association with systemic autoimmune, vasculitic or autoinflammatory disorders. Its diagnosis remains difficult because progressive or fluctuating hearing loss is not specific to immune-mediated cochlear injury, and no disease-specific biomarker has been validated. This review examines AIED from the combined perspectives of otology and rheumatology, focusing on systemic disease associations, pathogenic mechanisms, diagnostic limitations and therapeutic evidence. Experimental studies implicate blood–labyrinth barrier disruption, inflammatory cell recruitment, adaptive immune responses and microvascular injury, although direct confirmation of these mechanisms in primary human AIED remains limited. Clinically, serial audiometry, exclusion of alternative causes and targeted assessment for systemic inflammatory disease remain central to evaluation. Corticosteroids are commonly used as initial treatment, but therapeutic responsiveness does not establish the diagnosis. Evidence supporting conventional immunosuppressants and biologic agents remains insufficient for routine application in primary AIED. We distinguish findings obtained directly from patients with suspected AIED from evidence derived from related systemic disorders and experimental models, and identify the methodological priorities needed to improve diagnostic classification and treatment evaluation.
- 3 November 2026
- Published by UK Scientific Publishing Limited in ENT Updates
- Vol. 16 (4) , 24-49
Open AccessAutoimmune Inner Ear Disease at the Otology–Rheumatology Interface: Mechanisms, Diagnosis and Treatment
Autoimmune inner ear disease (AIED) encompasses immune-mediated sensorineural hearing loss occurring either in isolation or in association with systemic autoimmune, vasculitic or autoinflammatory disorders. Its diagnosis remains difficult because progressive or fluctuating hearing loss is not specific to immune-mediated cochlear injury, and no disease-specific biomarker has been validated. This review examines AIED from the combined perspectives of otology and rheumatology, focusing on systemic disease associations, pathogenic mechanisms, diagnostic limitations and therapeutic evidence. Experimental studies implicate blood–labyrinth barrier disruption, inflammatory cell recruitment, adaptive immune responses and microvascular injury, although direct confirmation of these mechanisms in primary human AIED remains limited. Clinically, serial audiometry, exclusion of alternative causes and targeted assessment for systemic inflammatory disease remain central to evaluation. Corticosteroids are commonly used as initial treatment, but therapeutic responsiveness does not establish the diagnosis. Evidence supporting conventional immunosuppressants and biologic agents remains insufficient for routine application in primary AIED. We distinguish findings obtained directly from patients with suspected AIED from evidence derived from related systemic disorders and experimental models, and identify the methodological priorities needed to improve diagnostic classification and treatment evaluation.
- 2 April 2024
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 144 (4) , 313-319
Blood eosinophilia and a higher ethmoid sinus/maxillary sinus score ratio predict new-onset asthma in patients with chronic rhinosinusitis with nasal polyps
Backgroud: Presently, the impact of Chronic rhinosinusitis with nasal polyps (CRSwNP) on asthma onset is unknown. Aims: To evaluate the role of CRSwNP in asthma onset. Materials and Methods: A total of 3107 CRSwNP patients were retrospectively screened from 1 January 2018, to 31 May 2021; 624 patients were enrolled. Clinical data regarding nasal symptoms, Lund-Mackay scores, blood eosinophil percentage, and onset of asthma were analyzed. Patients were divided into different groups according to past history of nasal polyps, Lund-Mackay score, and the extent of blood eosinophilia. Asthma-free rates between these subgroups were analyzed by Kaplan-Meier curves and Cox regression models. Results: The prevalence of asthma was 10.90% in patients with CRSwNP, and new-onset asthma occurred in 3.14% of these patients. Higher Lund-Mackay scores for ethmoid sinus and maxillary sinus (E/M) and blood eosinophil percentages were two independent risk factors for new-onset asthma, with hazard ratios of 1.267 (95%CI, 1.155-1.390) and 1.224 (95%CI, 1.054-1.422), respectively. CRSwNP patients with an E/M ratio > 2.33 or a blood Eos percentage > 5.5% were at risk for asthma onset. Conclusions and significance: Blood eosinophilia and a higher E/M score ratio were associated with new-onset asthma in patients with CRSwNP.
- 2 April 2024
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 144 (4) , 313-319
Blood eosinophilia and a higher ethmoid sinus/maxillary sinus score ratio predict new-onset asthma in patients with chronic rhinosinusitis with nasal polyps
Backgroud: Presently, the impact of Chronic rhinosinusitis with nasal polyps (CRSwNP) on asthma onset is unknown. Aims: To evaluate the role of CRSwNP in asthma onset. Materials and Methods: A total of 3107 CRSwNP patients were retrospectively screened from 1 January 2018, to 31 May 2021; 624 patients were enrolled. Clinical data regarding nasal symptoms, Lund-Mackay scores, blood eosinophil percentage, and onset of asthma were analyzed. Patients were divided into different groups according to past history of nasal polyps, Lund-Mackay score, and the extent of blood eosinophilia. Asthma-free rates between these subgroups were analyzed by Kaplan-Meier curves and Cox regression models. Results: The prevalence of asthma was 10.90% in patients with CRSwNP, and new-onset asthma occurred in 3.14% of these patients. Higher Lund-Mackay scores for ethmoid sinus and maxillary sinus (E/M) and blood eosinophil percentages were two independent risk factors for new-onset asthma, with hazard ratios of 1.267 (95%CI, 1.155-1.390) and 1.224 (95%CI, 1.054-1.422), respectively. CRSwNP patients with an E/M ratio > 2.33 or a blood Eos percentage > 5.5% were at risk for asthma onset. Conclusions and significance: Blood eosinophilia and a higher E/M score ratio were associated with new-onset asthma in patients with CRSwNP.
- Open Access
- 21 November 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (6) , 604-652
Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update
Wang C, et al. Allergy Asthma Immunol Res. 2022 Nov;14(6):604-652. https://doi.org/10.4168/aair.2022.14.6.604
- 21 November 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (6) , 604-652
Open AccessChinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update
Wang C, et al. Allergy Asthma Immunol Res. 2022 Nov;14(6):604-652. https://doi.org/10.4168/aair.2022.14.6.604
- 7 September 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (9) , 2487-2488
Reply to “The confounding effect of baselined characteristics in the assessment of efficacy of biologics”
- 7 September 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (9) , 2487-2488
Reply to “The confounding effect of baselined characteristics in the assessment of efficacy of biologics”
- Top Cited Papers
- 7 March 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (7) , 1876-1886.e7
Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis
- 7 March 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (7) , 1876-1886.e7
Top Cited PapersComparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis
- 29 November 2021
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 36 (3) , 330-338
Effects of Acute Alcohol Intake on Nasal Patency
Acute alcohol intake may influence nasal patency; however, there is lack of objective evidence. The aim of this study was to evaluate the effects of acute alcohol intake on nasal patency employing both subjective and objective measures. A total of 31 participants were classified into 2 groups of non-heavy drinkers (n = 17) and heavy drinkers (n = 14). Both groups consumed wine in 1 h and were assessed for subjective nasal symptoms and objective nasal patency, using rhinomanometry and acoustic rhinometry, at baseline and at 0.5, 2, and 6 h post-alcohol consumption. Alcohol consumption significantly increased nasal obstruction from baseline values in both heavy and non-heavy drinking groups. Total nasal volume (TNV) and the minimal cross-sectional area (MCA) were significantly decreased and nasal airway resistance (NAR) significantly increased from baseline values by 2 h post-alcohol consumption for both heavy and non-heavy drinking groups (P < .05). Significant differences were found in TNV, MCA, and NAR between baseline and post-drinking in allergic rhinitis subjects; with no significant differences in MCA and NAR in subjects without allergic rhinitis. Pulse rate (PR) and temperature (T) were elevated, and blood pressure (BP) was decreased after alcohol consumption (P < .05). Blood alcohol concentration (BAC) was not significantly correlated with nasal patency with regard to any subjective or objective measurement. Acute alcohol consumption may impair nasal patency, independent of the amount consumed. Individuals with allergic rhinitis may be more prone to nasal obstruction after alcohol consumption than those without allergic rhinitis.
- 29 November 2021
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 36 (3) , 330-338
Effects of Acute Alcohol Intake on Nasal Patency
Acute alcohol intake may influence nasal patency; however, there is lack of objective evidence. The aim of this study was to evaluate the effects of acute alcohol intake on nasal patency employing both subjective and objective measures. A total of 31 participants were classified into 2 groups of non-heavy drinkers (n = 17) and heavy drinkers (n = 14). Both groups consumed wine in 1 h and were assessed for subjective nasal symptoms and objective nasal patency, using rhinomanometry and acoustic rhinometry, at baseline and at 0.5, 2, and 6 h post-alcohol consumption. Alcohol consumption significantly increased nasal obstruction from baseline values in both heavy and non-heavy drinking groups. Total nasal volume (TNV) and the minimal cross-sectional area (MCA) were significantly decreased and nasal airway resistance (NAR) significantly increased from baseline values by 2 h post-alcohol consumption for both heavy and non-heavy drinking groups (P < .05). Significant differences were found in TNV, MCA, and NAR between baseline and post-drinking in allergic rhinitis subjects; with no significant differences in MCA and NAR in subjects without allergic rhinitis. Pulse rate (PR) and temperature (T) were elevated, and blood pressure (BP) was decreased after alcohol consumption (P < .05). Blood alcohol concentration (BAC) was not significantly correlated with nasal patency with regard to any subjective or objective measurement. Acute alcohol consumption may impair nasal patency, independent of the amount consumed. Individuals with allergic rhinitis may be more prone to nasal obstruction after alcohol consumption than those without allergic rhinitis.
- 1 September 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 127 (3) , 363-371.e1
Antihistamine premedication improves safety and efficacy of allergen immunotherapy
- 1 September 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 127 (3) , 363-371.e1
Antihistamine premedication improves safety and efficacy of allergen immunotherapy
- Open Access
- 7 January 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Reduced Expression of Antimicrobial Protein Secretory Leukoprotease Inhibitor and Clusterin in Chronic Rhinosinusitis with Nasal Polyps
Introduction. Antimicrobial peptides and proteins (AMPs) constitute the first line of defense against pathogenic microorganisms in the airway. The association between AMPs and chronic rhinosinusitis with nasal polyps (CRSwNP) requires further investigations. This study is aimed at investigating the expression and regulation of major dysregulated AMPs in the nasal mucosa of CRSwNP. Methods. The expression of AMPs was analyzed in nasal tissue from patients with eosinophilic (E) CRSwNP and nonECRSwNP and healthy subjects using RNA sequencing. The 10 most abundant AMPs expressed differentially in CRSwNP patients were verified by real-time PCR, and of these, the expression and regulation of secretory leukoprotease inhibitor (SLPI) and clusterin (CLU) were investigated further. Results. The 10 most abundant AMPs expressed differentially in CRSwNP compared to healthy control, regardless of subtypes, included BPIFA1, BPIFB1, BPIFB2, CLU, LTF, LYZ, and SLPI, which were downregulated, and S100A8, S100A9, and HIST1H2BC, which were upregulated. ELISA and immunofluorescence confirmed the decreased expression of SLPI and CLU levels in CRSwNP. SLPI is expressed in both nasal epithelial cells and glandular cells, whereas CLU is mainly expressed in glandular cells. AB/PAS staining further demonstrated that both SLPI and CLU were mainly produced by mucous cells in submucosal glands. Furthermore, the numbers of submucosal glands were significantly decreased in nasal polyp tissue of CRSwNP compared to nasal tissue of controls. SLPI was downregulated by TGF-β1 and IL-4 in cultured nasal tissues in vitro, while CLU expression was inhibited by TGF-β1. Glucocorticoid treatment for 2 weeks significantly increased the expression of all downregulated AMPs, but not LYZ. Additionally, budesonide significantly increased the expression of SLPI and CLU in cultured nasal tissues. Conclusion. The expression of major antimicrobial proteins is significantly decreased in nasal tissue of CRSwNP. The expression of SLPI and CLU is correlated with the numbers of submucosal glands and regulated by inflammatory cytokines and glucocorticoids.
- 7 January 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Open AccessReduced Expression of Antimicrobial Protein Secretory Leukoprotease Inhibitor and Clusterin in Chronic Rhinosinusitis with Nasal Polyps
Introduction. Antimicrobial peptides and proteins (AMPs) constitute the first line of defense against pathogenic microorganisms in the airway. The association between AMPs and chronic rhinosinusitis with nasal polyps (CRSwNP) requires further investigations. This study is aimed at investigating the expression and regulation of major dysregulated AMPs in the nasal mucosa of CRSwNP. Methods. The expression of AMPs was analyzed in nasal tissue from patients with eosinophilic (E) CRSwNP and nonECRSwNP and healthy subjects using RNA sequencing. The 10 most abundant AMPs expressed differentially in CRSwNP patients were verified by real-time PCR, and of these, the expression and regulation of secretory leukoprotease inhibitor (SLPI) and clusterin (CLU) were investigated further. Results. The 10 most abundant AMPs expressed differentially in CRSwNP compared to healthy control, regardless of subtypes, included BPIFA1, BPIFB1, BPIFB2, CLU, LTF, LYZ, and SLPI, which were downregulated, and S100A8, S100A9, and HIST1H2BC, which were upregulated. ELISA and immunofluorescence confirmed the decreased expression of SLPI and CLU levels in CRSwNP. SLPI is expressed in both nasal epithelial cells and glandular cells, whereas CLU is mainly expressed in glandular cells. AB/PAS staining further demonstrated that both SLPI and CLU were mainly produced by mucous cells in submucosal glands. Furthermore, the numbers of submucosal glands were significantly decreased in nasal polyp tissue of CRSwNP compared to nasal tissue of controls. SLPI was downregulated by TGF-β1 and IL-4 in cultured nasal tissues in vitro, while CLU expression was inhibited by TGF-β1. Glucocorticoid treatment for 2 weeks significantly increased the expression of all downregulated AMPs, but not LYZ. Additionally, budesonide significantly increased the expression of SLPI and CLU in cultured nasal tissues. Conclusion. The expression of major antimicrobial proteins is significantly decreased in nasal tissue of CRSwNP. The expression of SLPI and CLU is correlated with the numbers of submucosal glands and regulated by inflammatory cytokines and glucocorticoids.
Artemisia annua‐sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial
Background: Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua‐sublingual immunotherapy (SLIT).Methods: This was a randomized, double‐blind, placebo‐controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua‐SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow‐up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported.Results: Artemisia annua‐SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua‐SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua‐SLIT.Conclusion: Artemisia annua‐SLIT is an efficacious and safe treatment in patients with A annua SAR.
Artemisia annua‐sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial
Background: Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua‐sublingual immunotherapy (SLIT).Methods: This was a randomized, double‐blind, placebo‐controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua‐SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow‐up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported.Results: Artemisia annua‐SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua‐SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua‐SLIT.Conclusion: Artemisia annua‐SLIT is an efficacious and safe treatment in patients with A annua SAR.